Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

3.580 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,222
Open 3.600
Bid (Size) 3.580 (2)
Ask (Size) 3.650 (28)
Prev. Close 3.580
Today's Range 3.480 - 3.680
52wk Range 3.030 - 22.94
Shares Outstanding 5,007,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga

Performance

YTD
-57.48%
-57.48%
1 Month
-20.80%
-20.80%
3 Month
-43.17%
-43.17%
6 Month
-54.51%
-54.51%
1 Year
-83.84%
-83.84%

More News

Read More
Recap: Aptevo Therapeutics Q1 Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Aptevo Therapeutics
Via AccessWire
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
From Aptevo Therapeutics
Via AccessWire
Why Are Aptevo Therapeutics Shares Trading Higher Today?
Via Benzinga
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 150 Points; Emclaire Financial Shares Spike Higher
Via Benzinga
Why Did Aptevo Therapeutics Stock Jump 25% Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Mid-Day Market Update: Dow Surges 250 Points; LiqTech International Shares Slide
Via Benzinga
34 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Aptevo Therapeutics: Q4 Earnings Insights
Via Benzinga
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
From Aptevo Therapeutics
Via AccessWire
60 Biggest Movers From Yesterday
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
From Aptevo Therapeutics
Via AccessWire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
From Aptevo Therapeutics
Via AccessWire
Topics Retirement
Exposures Pension
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
From Aptevo Therapeutics
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.